Navigation Links
New Data Presented on the Renessa(R) Treatment for Female Stress Urinary Incontinence
Date:11/9/2007

6 month results from long term durability study presented at Western

Section meeting of the American Urological Association

NEWARK, Calif., Nov. 9 /PRNewswire/ -- Novasys Medical, Inc., a developer of innovative therapies in women's health, announced today that six month data from its post-market, prospective open label study to evaluate the long term durability of the Renessa(R) treatment for stress urinary incontinence (SUI) in women was presented at the Western Section meeting of the American Urological Association (AUA). A total of 137 women in the trial have been treated at 13 different sites across the United States. The patients will be followed for three years post-treatment.

Denise Elser, M.D., a urogynecologist practicing in Oak Lawn, Illinois and the principal investigator in the trial, presented the data in Scottsdale, AZ. "The non-surgical Renessa procedure offers women suffering from the isolating effects of SUI a safe, effective alternative between conservative treatments such as Kegel exercises and biofeedback, and more invasive surgical therapies," Dr. Elser said. "Women are looking for an alternative to exercise and surgery. My patients and I have been very pleased with the safety and results of this noninvasive treatment," she continued. The trial results will also be presented during a poster session at the upcoming Global Congress of Minimally Invasive Gynecology in Washington, DC.

Highlights of the six month results include:

-- 74% of women showed an improvement in their symptoms with 63% of women

reducing their episodes to less than half

-- 74% of women reported improvement in their quality of life

"This multi-center three year prospective trial is expected to confirm the outcomes seen in our previous U.S. Pivotal Trial," said Charles S. Carignan, M.D., Chief Medical Officer of Novasys Medical. "The six month results so far not only validate our earlier studies, but outcomes
'/>"/>

SOURCE Novasys Medical, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 2015  BioPhotas, Inc., an FDA registered medical device ... technologies to treat skin, muscle and joint conditions, today ... Fund to provide BioPhotas, flagship product, the Celluma, ... solutions.  Commenting on the alliance, ... the Celluma at the Warrior Hope and Care Center ...
(Date:3/5/2015)... HAMILTON, N.J. , March 5, 2015 /PRNewswire/ ... laboratory which specializes in high complexity, state-of-the-art, automated ... offering new Human Papillomavirus (HPV) testing which utilizes ... platforms. Each year, approximately 12,000 women ... the United States . Genital Human Papillomaviruses ...
(Date:3/5/2015)... 2015  ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ... acquired the approved abbreviated new drug application ("ANDA") ... 150mg, previously marketed by Teva Pharmaceuticals.  According to ... was approximately $39 million in 2014.   ... CEO of ANI Pharmaceuticals, stated, "This acquisition further ...
Breaking Medicine Technology:BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 2BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 3Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 2Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 3ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 2ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 3
... 2011 /PRNewswire/ -- MEDX, Inc., a ... the next generation T-Quest™ compact gamma camera.  The ... features expanded imaging capabilities to perform parathyroid, sentinel ... other small organ studies.  The Company also announced ...
... 6, 2011 Life Extension, a global authority on ... supplements, has launched a product featuring ChromaDex,s (CDXC.OB) pTeroPure ... food stores and natural retailers. Life Extension ... naturally found in blueberries.  Pterostilbene has been shown ...
Cached Medicine Technology:MEDX Installs Two Next Generation T-Quest™ Compact Gamma Cameras 2MEDX Installs Two Next Generation T-Quest™ Compact Gamma Cameras 3Life Extension® Launches New Product Containing ChromaDex's pTeroPure® Pterostilbene 2Life Extension® Launches New Product Containing ChromaDex's pTeroPure® Pterostilbene 3
(Date:3/5/2015)... 2015 Dr. Jonathan Glashow a board ... has been named by Castle Connolly as ... Dr. Glashow has been selected by Castle Connolly Medical ... top specialty care doctors in the tri-state metropolitan New ... program, which carefully screens and selects doctors through a ...
(Date:3/5/2015)... 2015 As a result of ... of Clearstream, LLC ’s products, services and ... line of products—led by their mPulse Hand Sanitizer—fits ... Program. , The AAPA—which represents a profession comprising ... and surgical specialties in the U.S.—advocates and educates ...
(Date:3/5/2015)... Today, Earth Source Organics (ESO) ... pollution-free electricity through a partnership with national Clean ... Arcadia Power Clean Energy Partner, ESO now meets ... requirements, joining national brands such as Whole Foods, ... Earth Source Organics joins a growing community of ...
(Date:3/5/2015)... 05, 2015 The Journal of ... a special issue devoted entirely to ... PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococci) ... reaction triggered by infections such as strep throat, ... inflammation of the child's brain. This inflammation causes ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Think it’s tough ... even tougher to get them to brush their teeth. That’s ... parents released today by Delta Dental(1) in conjunction with National ... (45 percent) say getting kids to brush their teeth is ... to do. That’s slightly higher than getting children to eat ...
Breaking Medicine News(10 mins):Health News:Dr. Jonathan Glashow, NYC Orthopedic Surgeon, Named Top Doctor: New York Metro Area 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 3Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 4Health News:Earth Source Organics to Run on Clean Energy from Arcadia Power 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 3Health News:Delta Dental Survey Says Parents Have Harder Time Getting Kids to Brush than to Eat Vegetables 2Health News:Delta Dental Survey Says Parents Have Harder Time Getting Kids to Brush than to Eat Vegetables 3
... Calif., March 20 A former astronaut and veteran ... director of business development for Wyle,s Integrated Science and ... joins Wyle to assist in the company,s continued growth ... and performance services to the Federal Government. He will ...
... the advancement of imaging techniques, the accuracy of preoperative ... of physical function in rectal cancer patients has become ... research article to be published on March 14, 2009 ... the prognostic factors for 5-year survival after local excision ...
... in patients with atrial fibrillation. In the current edition ... 2009; 106(10): 164-70), Thomas Bitter and his coauthors from ... breathing occurs in this form of cardiac arrythmia and ... used cardiorespiratory polygraphy to investigate whether 150 patients (110 ...
... Boehringer Ingelheim today announced that the last ... Randomized Evaluation of Long term Anticoagulant therapy (RE-LY(R)) ... safety of the oral direct thrombin inhibitor dabigatran ... international normalized ratio, INR, 2-3) for the prevention ...
... Even finding it early may not save lives, researchers say, ... that combines ultrasound and a blood test to detect CA125, ... in its early stages and often results in unnecessary surgery, ... recent study that found that these same two tests did ...
... in European UnionCorporate Highlights:- CHMP issued positive ... for treatment of peripheral neuropathic pain in ... with other medicinal products for pain- Qutenza ... for PHNUpcoming 2009 Milestones:- European commercial partnership ...
Cached Medicine News:Health News:Veteran Astronaut Joins Wyle Business Development Staff in Houston 2Health News:Final Patient Completes Treatment In Boehringer Ingelheim's RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date 2Health News:Final Patient Completes Treatment In Boehringer Ingelheim's RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date 3Health News:Final Patient Completes Treatment In Boehringer Ingelheim's RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date 4Health News:Combo Screening Doesn't Spot Early Ovarian Cancer 2Health News:Combo Screening Doesn't Spot Early Ovarian Cancer 3Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 2Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 3Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 4Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 5Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 6Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 7Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 8Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 9Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 10Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 11
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: